Sometimes your team loses the game but still wins overall -- just like the U.S. soccer team this week, which lost to Germany yet still advanced to the next round of the World Cup. Other times, though, your team just loses. That's the case with three health-care stocks experiencing double-digit losses this week.
One of our big decliners lost its CEO to a development-stage biotech. Another announced a delay in the release of highly anticipated clinical study results. And the third didn't report any news -- good or bad, but shares still took a beating.
Which health-care stocks were crushed by the market this week? Find out by watching the slideshow below.
Leaked: The next huge opportunity?
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.